Kanaphtx

2 known investors

Kanaph Therapeutics is a biotech company developing novel cancer and eye-disease therapeutics based on human genome analysis, with a pipeline spanning bispecific antibodies, small-molecule drugs, and antibody-drug conjugates (ADCs). Its candidates target solid tumors (e.g. FAP-targeted IL-12, EP2/EP4, SHP2 and SOS1 inhibitors) as well as retinal conditions such as wet AMD and geographic atrophy.

BiotechHealthtech